Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study

Published:2020-05 Issue:5 Volume:7 Page:e395-e407
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Richardson Paul G,Bringhen Sara,Voorhees Peter,Plesner Torben,Mellqvist Ulf-Henrik,Reeves Brandi,Paba-Prada Claudia,Zubair Hanan,Byrne Catriona,Chauhan Dharminder,Anderson Kenneth,Nordström Eva,Harmenberg Johan,Palumbo Antonio,Sonneveld Pieter

Publisher

Elsevier BV

Subject

Hematology

Reference28 articles.

1. Multiple myeloma;Kumar;Nat Rev Dis Primers,2017

2. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study;Kumar;Leukemia,2017

3. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;Richardson;N Engl J Med,2005

4. Targeting CD38 with daratumumab monotherapy in multiple myeloma;Lokhorst;N Engl J Med,2015

5. Treatment of relapsed/refractory multiple myeloma;Kastritis;Semin Hematol,2009

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22

2. Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions;Pharmaceuticals;2024-06-25

3. Dose Optimization of Targeted Therapies for Oncologic Indications;Cancers;2024-06-09

4. PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-06